CAV1 and prostate carcinoma: Among the significant analyses, 70% of the study revealed that CAV1 and CAV2 were all significantly downregulated in most tumor types, especially in BC, lung cancer, ovarian cancer, prostate cancer, bladder cancer, and sarcoma cancer.